4-bromo-5-(cyclopropylmethyl)-1-methyl-1H-pyrazole | 2079069-45-5

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 4-bromo-5-(cyclopropylmethyl)-1-methyl-1H-pyrazole
• 英文别名: 4-bromo-5-(cyclopropylmethyl)-1-methylpyrazole
• CAS: 2079069-45-5
• 化学式: C₈H₁₁BrN₂
• 分子量: 215.09
• InChiKey: MRIGFESRPAHEEG-UHFFFAOYSA-N

物化性质

• 沸点：
  282.7±20.0 °C(Predicted)
• 密度：
  1.63±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Pyrazole compounds and uses thereof
  申请人：Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

  公开号：US11072599B2

  公开（公告）日：2021-07-27

  The present invention provides pyrazole derivatives of Formula (I), and in particular N1-(4-(5-(cyclopropylmethyl)-1-methyl-1H-pyrazol-4-yl) pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as casein kinase 1 (CK1) and/or interleukin 1 receptor associated kinase 1 (IRAKI) inhibitors for treating cancer, inflammatory and immune related disorders.

  本发明提供了式(I)的吡唑衍生物，特别是N1-(4-(5-(环丙基甲基)-1-甲基-1H-吡唑-4-基)吡啶-2-基)环己烷-1,4-二胺衍生物和相关化合物，作为酪蛋白激酶1（CK1）和/或白细胞介素1受体相关激酶1（IRAKI）抑制剂，用于治疗癌症、炎症和免疫相关疾病。
• [EN] HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF<br/>[FR] COMPOSÉ HÉTÉROCYLIQUE, COMPOSITION PHARMACEUTIQUE ET UTILISATION ASSOCIÉES<br/>[ZH] 一种杂环化合物、其药物组合物及用途
  申请人：BEIJING GUOHONG BIOMEDICAL TECH CO LTD

  公开号：WO2021000957A1

  公开（公告）日：2021-01-07

  一种杂环化合物或其药学上可接受的盐、溶剂化物、活性代谢物、多晶型物、同位素标记物或异构体及其用途，该杂环化合物的结构如式（I）或（II）。杂环化合物具有良好的CKIα-CDK7/9抑制活性。
• N1-(4-(5-(CYCLOPROPYLMETHYL)-1-METHYL-1H-PYRAZOL-4-YL)PYRIDIN-2-YL)CYCLOHEXANE-1,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS CK1 AND/OR IRAK1 INHIBITORS FOR TREATING CANCER
  申请人：Yissum Research Development Company of the Hebrew University of Jerusalem Ltd

  公开号：EP3577108B1

  公开（公告）日：2021-10-20
• PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF
  申请人：Yissum Research Development Company of the Hebrew University of Jerusalem LTD.

  公开号：US20180214447A1

  公开（公告）日：2018-08-02

  The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or Interleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.
• PYRAZOLE COMPOUNDS AND USES THEREOF
  申请人：Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

  公开号：US20220017493A1

  公开（公告）日：2022-01-20

  The present invention provides pyrazole derivatives, e.g., a compound of Formula (I), and their uses in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.